GIP and metabolic dysfunction-associated steatotic liver disease: Recently, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist Tirzepatide (LY3298176) significantly reduced NASH and fibrosis biomarkers in patients with T2DM.163,164 Another dual GIP/GLP-1 receptor agonist NNC0090-2746 improved glycemic control and reduced body weight and TC.165 In addition, a balanced glucagon-GLP-1 receptor agonist (Cotadutide) was observed to improve lipid profile, hepatic function indexes, and NAFLD fibrosis markers in type 2 diabetes patients controlled with Metformin.166